Enhanced Malaria Vaccine Compositions and Methods

Publication ID: 24-11857611_0001_PTD

Published: October 28, 2025

Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Malaria Vaccine Compositions and Methods,” Published Technical Disclosure No. 24-11857611_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857611_0001_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,611.

Summary of the Inventive Concept

Improved recombinant MVA viral vectors for generating an immune response to malaria, featuring novel adjuvants, immune-modulating proteins, and enhanced vector stability and durability.

Background and Problem Solved

The original patent described recombinant MVA viral vectors for malaria immunization, but these vectors had limitations in terms of immunogenicity, safety, and durability. The new inventive concept addresses these limitations by introducing novel adjuvants, immune-modulating proteins, and vector enhancements, resulting in improved vaccine compositions and methods.

Detailed Description of the Inventive Concept

The enhanced malaria vaccine compositions and methods comprise recombinant MVA viral vectors with novel adjuvants, such as toll-like receptor agonists, to enhance immunogenicity. Additionally, the vectors may include immune-modulating proteins, such as cytokines, to regulate the immune response. Furthermore, the vectors may be engineered to include proteins that enhance vector stability and durability, ensuring a more sustained immune response. The new claims describe specific formulations and methods for preventing or treating malaria, including boosting and priming regimens.

Novelty and Inventive Step

The new claims introduce novel adjuvants, immune-modulating proteins, and vector enhancements, which are not obvious from the original patent. The combination of these elements provides a significant improvement in immunogenicity, safety, and durability, making the new inventive concept novel and non-obvious.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept may include different adjuvants, immune-modulating proteins, or vector enhancements. For example, other toll-like receptor agonists or cytokines could be used, or different insertion sites for the nucleic acid sequences could be explored. Additionally, the recombinant MVA viral vectors could be formulated with other immunogenic polypeptides or used in combination with other vaccine platforms.

Potential Commercial Applications and Market

The enhanced malaria vaccine compositions and methods have significant commercial potential in the global vaccine market, particularly in regions where malaria is endemic. The improved safety, efficacy, and durability of the vaccine could lead to increased adoption and reduced healthcare costs.

CPC Classifications

Section	Class	Group
A	A61	A61K39/015
A	A61	A61K9/0019
A	A61	A61K47/6901
A	A61	A61P33/06
A	A61	A61K2039/5256
A	A61	A61K2039/54

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Vaccine development, immunology, and viral vector engineering, specifically focused on recombinant Modified Vaccinia Ankara (MVA) viral vectors for generating immune responses against infectious diseases like malaria

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with expertise in molecular virology, immunological engineering, vaccine design, and recombinant vector technologies, typically holding a PhD in immunology, microbiology, or related biomedical sciences with 3-5 years of specialized research experience

Obviousness Rationale

A person having ordinary skill in the art would recognize that enhancing MVA viral vectors through adjuvant incorporation, immune-modulating protein integration, and vector stability improvements represents a predictable and incremental advancement in vaccine design. The source patent establishes the foundational MVA vector technology for malaria immunization, and the published technical disclosure demonstrates straightforward engineering modifications that would be apparent to a skilled practitioner seeking to optimize vaccine performance and immunogenicity.

Obvious Combinations & Variations

Source Patent Element

Recombinant MVA viral vector with nucleic acid sequences encoding Plasmodium falciparum immunogenic polypeptides

PTD Variation

Adding toll-like receptor agonists as novel adjuvants to enhance immunogenicity

Obviousness Reasoning

Adjuvant selection is a known technique for improving vaccine immune responses, and a PHOSITA would recognize that incorporating TLR agonists represents a predictable optimization strategy

Source Patent Element

MVA viral vector insertion sites between specific genes like I8R and G1L

PTD Variation

Inserting additional nucleic acid sequences encoding immune-modulating cytokines

Obviousness Reasoning

Gene insertion techniques are well-established, and a skilled researcher would understand that modifying vector genetic content to include immunoregulatory proteins is a routine engineering approach

Source Patent Element

Recombinant MVA vector for generating immune response to malaria

PTD Variation

Incorporating proteins that enhance vector stability and durability

Obviousness Reasoning

Improving viral vector performance through genetic modifications is a standard approach in vaccine development, and a PHOSITA would find such enhancements an obvious extension of existing technologies

Source Patent Element

Malaria vaccine composition using MVA viral vector

PTD Variation

Developing boosting and priming regimens with enhanced vector configurations

Obviousness Reasoning

Vaccine dosing strategies and vector optimization are predictable design choices within the field, representing incremental improvements a skilled researcher would readily conceive

Source Patent Element

Nucleic acid sequences encoding immunogenic polypeptides

PTD Variation

Adding sequences for safety-enhancing proteins to modify vector characteristics

Obviousness Reasoning

Genetic engineering of viral vectors to improve safety profiles is a well-known technique, and a PHOSITA would recognize multiple potential approaches to achieving this goal

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857611 and the published technical disclosure, a person having ordinary skill in the art would find the claimed variations in malaria vaccine composition and MVA viral vector design to be obvious extensions of the prior art, rendering subsequent claims involving similar technological modifications anticipated and unpatentable under 35 U.S.C. Section 103.

Original Patent Information

Patent Number	US 11,857,611
Title	Compositions and methods for generating an immune response to treat or prevent malaria
Assignee(s)	GeoVax, Inc.